Takeda Masayuki

タケダマサユキ | Takeda Masayuki

Affiliation and department：

Research field (1)： Respiratory medicine

Research keywords (6)：ゲノム医療 , 支持療法 , 耐性機序 , 感受性因子 , 肺癌 , 分子標的薬

Research theme for competitive and other funds (7)：

2019 - 2022 クリニカルシーケンスにて同定される新規遺伝子変異の機能解析
2019 - 2021 がんゲノム医療に携わる医師等の育成に資する研究
2019 - 次世代シークエンサー等を用いた遺伝子パネル検査に基づくがん診療ガイダンス改訂のための研究
2016 - 2018 がんゲノム個別化医療の実現に向けた遺伝子診断共通カリキュラム構築と教育・研修プログラムの実証的開発研究
2017 - 2017 遺伝子パネル検査に係わる対象疾患等の検討に資するガイダンス作成のための研究

Show all

Papers (198)：

Ayako Yokomizo, Kazuhisa Nakashima, Arisa Iba, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, et al. Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology. International Journal of Clinical Oncology. 2024
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, et al. Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]. Lung cancer (Amsterdam, Netherlands). 2024. 193. 107852-107852
Hirotoshi Iihara, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-Il Kim, Hidenori Sasaki, et al. 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. International Journal of Clinical Oncology. 2024
Hiroaki Kanemura, Toshihide Yokoyama, Ryu Nakajima, Atsushi Nakamura, Hiroaki Kuroda, Yoshitaka Kitamura, Hiroyasu Shoda, Nobuaki Mamesaya, Yoshihiro Miyata, Tatsuro Okamoto, et al. The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma. JTO clinical and research reports. 2024. 5. 4. 100658-100658
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. Journal of Clinical Investigation. 2024. 134. 7

ｍore...

MISC (234)：

Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Kazuko Sakai, Maki Kobayashi, Ryoto Yoshimoto, et al. EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402. ANNALS OF ONCOLOGY. 2021. 32. S296-S296
武田真幸, 武田真幸, 中川和彦, 林秀敏, 岩朝勤, 川上尚人, 渡邉諭美, 山本昇, 米盛勧, 小山隆文, et al. ベンダムスチン塩酸塩経口剤(SyB C-0501)の進行性固形がん患者に対する第1相臨床試験. 日本癌治療学会学術集会(Web). 2021. 59th
金村宙昌, 田中薫, 鈴木慎一郎, 黒崎隆, 磯本晃佑, 岩朝勤, 白石直樹, 林秀敏, 武田真幸, 中川和彦. 気管支鏡検査時の迅速細胞診(ROSE)の成功に関連する因子の検討. 気管支学. 2021. 43
西郷和真, 池川敦子, 木戸滋子, 川上尚人, 武田真幸, 岩朝勤, 巽純子, 福岡和也, 西尾和人, 田村和朗, et al. コロナ下の近畿大学病院遺伝子診療部における状況. 日本遺伝カウンセリング学会誌. 2021. 41. 4
佐藤千尋, 林秀敏, 田中薫, 武田真幸, 中川和彦, 坂井和子, 西尾和人. 免疫チェックポイント阻害薬奏効後に転移巣増大を来した肺癌症例の遺伝子的検討. 肺癌(Web). 2020. 60. 2

ｍore...

Patents (1)：

Method using a ret fusion gene as a biomarker to select non-small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment

Lectures and oral presentations (20)：

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancer
(Cancer Res (2021) 81 (13_Supplement): CT011. 2021)
A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
(AACR 2019 2019)
T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive NSCLC
(World Conference on Lung Cancer 2017 2017)
A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC)
(World Conference on Lung Cancer 2017 2017)
Phase 2 Study of Ceritinib in Patients with ALK+ NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
(World Conference on Lung Cancer 2017 2017)

ｍore...

Committee career (16)：

2021 - 現在日本癌学会評議員
2021 - 現在日本臨床腫瘍学会協議員
2020 - 現在 International Cancer Conference Journal (ICCJ)編集部会委員
2020 - 現在癌治療学会編集委員会委員
2019 - 現在 JSCO/JSMO/ ASCO/ ESMO/ TOS international expert opinion paper for tumor-agnostic treatments in patients with advanced solid tumors 作成委員

Show all

Awards (10)：

2021 - 西日本がん研究機構(WJOG)有吉・福岡賞
2018 - 日本肺癌学会肺癌研究助成
2018 - 大阪コミュニティ財団「がん研究助成」
2018 - 武田科学振興財団医学系研究助成
2016 - 日本肺癌学会優秀ポスター賞

Show all

Association Membership(s) (7)：

日本サポーティブケア学会 , IASLC , JAPAN SOCIETY OF CLINICAL ONCOLOGY , THE JAPANESE CANCER ASSOCIATION , 日本臨床腫瘍学会 , THE JAPAN LUNG CANCER SOCIETY , THE JAPANESE SOCIETY OF INTERNAL MEDICINE

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page